Among these different CAF subtypes, iCAFs are reported to have a particular effect on chemoresistance in breast cancer patients [40, 86], probably due to their high secretion of cytokines involved in therapy resistance, such as CXCL1–3, CCL2, CSF3, CXCL10, IL1β and LIF. This evidence concerns the gene CXCL10 and breast carcinoma.